

**In the Claims:**

Please enter the following amendments without prejudice or disclaimer. This listing of claims will replace all prior versions, and listings, of claims in the application.

Please cancel claims 2, 4, 6, 15- 23, 33-38 and 42-47 without prejudice.

Please amend claims 1, 3, 5, 7, 8, 10, 51, 52 and 55-57, and add new claims 58-62, as shown below:

1. (currently amended) A method for treating and/or ameliorating [the] a symptom[s] of neuronal damage associated with a cerebral ischemic condition in a mammalian subject, comprising administering to the subject an effective amount of a non-alpha tocopherol metabolite enriched tocopherol composition, wherein said non-alpha tocopherol metabolite is selected from the group consisting of a metabolite of beta-tocopherol, a metabolite of gamma-tocopherol and a metabolite of delta-tocopherol; and by said administering, reducing neuronal damage related to said cerebral ischemic condition.

2. (canceled)

3. (currently amended) The method of claim 1 wherein the non-alpha tocopherol metabolite enriched tocopherol composition is a gamma-tocopherol metabolite enriched composition.

4. (canceled)

5. (currently amended) The method of claim 1 wherein the non-alpha tocopherol metabolite enriched tocopherol composition is a beta-tocopherol metabolite enriched composition.

6. (canceled)

7. (currently amended) The method of claim 1 wherein the non-alpha tocopherol metabolite enriched tocopherol composition is a delta-tocopherol metabolite enriched composition.

8. (currently amended) The method of claim 3 wherein said gamma-tocopherol metabolite is ~~gamma-CEHC~~ 2,7,8-trimethyl-2-( $\beta$ -carboxy-ethyl)-6-hydroxy chroman ( $\gamma$ -CEHC).

9. (original) The method of claim 1 wherein the cerebral ischemic condition is secondary to an occlusion of the cerebral vasculature.

10. (currently amended) The method of claim 9 wherein the occlusion is due to a ~~thromboembolis~~ thromboembolus.

11. (original) The method of claim 1 wherein the cerebral ischemia is due to a spasm of the coronary vasculature.

12. (original) The method of claim 1 wherein the cerebral ischemic condition is secondary to a cessation of cardiac function.

13. (original) The method of claim 1 wherein the cerebral ischemic condition is secondary to a cardiopulmonary bypass procedure.

14. (original) The method of claim 1 wherein the cerebral ischemic condition is secondary to a hemorrhagic event in the cerebral vasculature.

15-23. (canceled)

24. (original) The method of claim 3 wherein said gamma-tocopherol metabolite enriched composition comprises at least 60% gamma-tocopherol metabolite.

25. (original) The method of claim 3 wherein said gamma-tocopherol metabolite enriched composition comprises at least 65% gamma-tocopherol metabolite.

26. (original) The method of claim 3 wherein said gamma-tocopherol metabolite enriched composition comprises at least 70% gamma-tocopherol metabolite.

27. (original) The method of claim 3 wherein said gamma-tocopherol metabolite enriched composition comprises at least 75% gamma-tocopherol metabolite.

28. (original) The method of claim 3 wherein said gamma-tocopherol metabolite enriched composition comprises at least 80% gamma-tocopherol metabolite.

29. (original) The method of claim 3 wherein said gamma-tocopherol metabolite enriched composition comprises at least 85% gamma-tocopherol metabolite.

30. (original) The method of claim 3 wherein said gamma-tocopherol metabolite enriched composition comprises at least 90% gamma-tocopherol metabolite.

31. (original) The method of claim 3 wherein said gamma-tocopherol metabolite enriched composition comprises at least 95% gamma-tocopherol metabolite.

32. (original) The method of claim 3 wherein said gamma-tocopherol metabolite enriched composition comprises at least 98% gamma-tocopherol metabolite.

33-38. (canceled)

39. (original) The method of claim 5 wherein said beta-tocopherol metabolite enriched composition comprises at least 50% beta-tocopherol metabolite.

40. (original) The method of claim 5 wherein said beta-tocopherol metabolite enriched composition comprises at least 65% beta-tocopherol metabolite.

41. (original) The method of claim 5 wherein said beta-tocopherol metabolite enriched composition comprises at least 90% beta-tocopherol metabolite.

42-47. (canceled)

48. (original) The method of claim 7 wherein said delta-tocopherol metabolite enriched composition comprises at least 50% delta-tocopherol metabolite.

49. (original) The method of claim 7 wherein said delta-tocopherol metabolite enriched composition comprises at least 65% delta-tocopherol metabolite.

50. (original) The method of claim 7 wherein said delta-tocopherol metabolite enriched composition comprises at least 90% delta-tocopherol metabolite.

51. (currently amended) The method of claim 1 wherein said non-alpha tocopherol metabolite enriched tocopherol composition is a nutritional composition.

52. (currently amended) The method of claim 1 wherein said non-alpha tocopherol metabolite enriched tocopherol composition is a pharmaceutical composition.

53. (original) The method of claim 1 wherein said composition is administered orally.

54. (original) The method of claim 1 wherein said composition is administered parenterally.

55. (currently amended) The method of claim 1 wherein said composition comprises a non-alpha tocopherol metabolite in a range of 1-1000 mg per kg body weight of said mammalian subject.

56. (currently amended) The method of claim 1 wherein said composition comprises a non-alpha tocopherol metabolite in a range of 1-50 mg per kg body weight of said mammalian subject.

57. (currently amended) The method of claim 1 wherein said composition comprises a non-alpha metabolite tocopherol in a range of 10-100 mg per kg body weight of said mammalian subject.

58. (new) The method of claim 1 wherein said neuronal damage is neuronal cell death.

59. (new) The method of claim 1 wherein said neuronal damage is total cerebral infarct volume.

60. (new) The method of claim 1 wherein said neuronal damage is total cerebral ischemic damage.

61. (new) The method of claim 1 wherein said neuronal damage is cerebral tissue edema.

62. (new) The method of claim 1 wherein said neuronal damage is cognitive dysfunction.